Fluidigm Cadmium Metal Labeling Kits for Mass Cytometry
Fluidigm has releases seven new Maxpar cadmium metal labeling kits for use with mass cytometry: 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, and 116Cd. Fluidigm said that the kits will allow researchers to easily expand mass cytometry panels as demand grows for larger panels to interrogate the immunome, cancer, and other complex diseases. When the labels are used with existing panels containing more than 20 parameters, researchers can simultaneously profile more than 50 cell surface and intracellular parameters in a single run. Researchers can also use the kits to customize Fluidigm pre-designed panels, including the Maxpar Direct Immune Profiling Assay, the firm said.
Roche Cobas EBV, BKV Tests
Roche has launched the Cobas EBV and BKV tests for Epstein-Barr virus and BK virus in countries that accept the CE mark. Users can run the tests with Roche's Cobas 6800/8800 Systems. The real-time PCR tests leverages dual target technology to help clinicians manage the risk of infection for severely immunocompromised transplant patients and assess if these patients are at risk of developing disease, which can contribute to organ rejection, the company said.
Sysmex Inostics SafeSeq Breast, Head and Neck Cancer Panels; Rapid Custom Development Program
Sysmex Inostics has launched its SafeSeq Breast Cancer and Head and Neck Cancer Panels, which both use the firm's SafeSeq next-generation sequencing approach. The SafeSeq Breast Cancer Panel tests for mutations affecting the PIK3CA, ESR1, TP53, ERBB2, AKT1, and KRAS genes in ER-positive HER2-negative breast cancer samples, the firm noted. The SafeSEQ Breast cancer panel offers sensitive detection of mutant ctDNA, which Sysmex believes is well suited for disease monitoring to assess treatment response, minimal residual disease, and molecular relapse. Sysmex's SafeSeq Head and Neck Cancer panel tests for mutations in the genes PIK3CA, CDKN2A, HRAS, and TP53.
In addition to the cancer panels, Sysmex now offers its SafeSeq Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. The firm said that users can assemble targeted genes and mutations into highly sensitive fit-for-purpose assays with customer-selected levels of analytical and clinical validation.
For more new products and services, please visit the New Products page on our website.